Skip to content
Hugin
An adult holding parallel support rails walks beside a person in blue scrubs; both are framed below the shoulders.

Hugin News

FDA approves Sunharbo to reduce stroke risk in a defined group of adults after stroke or high-risk TIA

2 min read

Original AI-generated editorial illustration for Hugin; a fictional rehabilitation scene, not a study participant or treatment result.

This record was prepared on the date shown and recovered after a publishing interruption.

FDA approved Sunharbo on November 9 for use with antiplatelet therapy after certain recent strokes or high-risk transient ischemic attacks. The agency reports a 26% lower ischemic-stroke risk than placebo in the study, alongside bleeding cautions. The drug is not approved to prevent stroke in patients with atrial fibrillation, and the reported reduction is relative rather than a percentage-point change.

healthdrug-approvalsstrokepatient-safetyfood-and-drug-administration
source receipt
1
source host
1
read time
2min
primary source
Linked

FDA approved Sunharbo (asundexian) 50 mg tablets on November 9 to reduce stroke risk in a defined group of adults, in combination with antiplatelet therapy. The agency says it is the first approved factor XIa inhibitor.

Who the approval covers

The indication covers adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack, often called a TIA. In the stroke group, the clot did not originate in the heart.

FDA explicitly says Sunharbo is not approved for stroke prevention in patients with atrial fibrillation. The approval therefore does not extend to every person who has had a stroke or has a risk factor for one.

The approval was granted to Bayer HealthCare Pharmaceuticals.

What FDA reports about the trial

The agency's announcement describes OCEANIC-STROKE as a randomized, double-blind, placebo-controlled phase 3 study involving 12,327 adults. Participants were assigned to Sunharbo or placebo within 72 hours of symptom onset. Both groups also received antiplatelet therapy.

FDA says the once-daily 50 mg treatment reduced ischemic-stroke risk by 26% compared with placebo, over a median treatment period of 14.2 months. That is a relative comparison, not a 26-percentage-point reduction. The release does not provide absolute event rates from which to calculate an individual patient's benefit.

The bleeding limits

FDA reports a similar overall major-bleeding rate between the treatment groups, but increased major bleeding with Sunharbo among patients older than 75 and during the first 90 days of treatment. Gastrointestinal bleeding was also more common with Sunharbo than placebo.

The announcement says Sunharbo is not recommended for patients with moderate or severe liver impairment, or for concurrent use with medicines that are combined P-gp and strong CYP3A4 inducers, such as carbamazepine, because they may reduce its effectiveness.

Those restrictions accompany the approval. The release is an agency summary, rather than the full prescribing information or an assessment of which treatment is appropriate for an individual patient.

Source links